about the author

ENDPOINTS

editor@endpointsnews.com

author articles

In­tel­lia ex­its he­mo­phil­ia B pact with Re­gen­eron; Sang­amo tar­gets $24M raise

Last year
News Briefing

Mei­ji Sei­ka Phar­ma to sup­ply Japan with self-am­pli­fy­ing mR­NA Covid-19 vac­cine in fall/win­ter of 2024

Last year
Nikkei Biotechnology

In­nate ends Ph1b in pe­riph­er­al T cell lym­phoma; Lay­offs at NextCure

Last year
News Briefing

Madri­gal's $600M of­fer­ing; PureTech to re­turn $100M to share­hold­ers

Last year
News Briefing

Blue­bird's $175M loan; Spyre re­veals sec­ond pri­vate place­ment

Last year
News Briefing

OcuTer­ra’s di­a­bet­ic retinopa­thy drug fails PhII; Bet­ter Ther­a­peu­tics to shut down

Last year
News Briefing

Reg­u­lus rais­es $100M; Can­cer com­pa­ny files to go pub­lic

Last year
News Briefing

Lex­eo brings in $95M; FDA lifts hold on Nurix can­cer tri­al

Last year
News Briefing

Ul­ti­movac­s' melanoma vac­cine fails in PhII; Re­genxbio’s $140M of­fer­ing

Last year
News Briefing

Bridge­Bio's $250M of­fer­ing; Vi­iV's PhI da­ta for ul­tra-long-act­ing HIV treat­ment

Last year
News Briefing

Viking's $350M of­fer­ing; Bak­er Broth­ers leads an­oth­er PIPE

Last year
News Briefing

De­nali’s $500M place­ment; Brain health start­up rais­es $26M

Last year
News Briefing

Mer­ri­mack to dis­solve af­ter record­ing $225M mile­stone; Co­gen­t's $225M place­ment

Last year
News Briefing

Ku­ra’s stock jumps on PhIb read­out; FDA lifts hold on IN­mune Bio pro­gram; Nanobi­otix’s $20M mile­stone

Last year
News Briefing

Mer­ck inks deal with Un­nat­ur­al Prod­ucts; CG On­col­o­gy’s up­sized IPO; Lo­cus gets $24M from BAR­DA

Last year
News Briefing

Doud­na’s new ven­ture; Aclaris CEO to step down; Tome’s $114M liv­er dis­or­der deal with Genevant

Last year
News Briefing

#JPM24 quick hits: Io­n­is on part­ner­ship’s pros and cons; No­vo Ven­tures has $600M to spend; Are small mol­e­cules ...

Last year
R&D

#JPM24 quick hits: Vibe check; Maze’s next turn; AI at phar­ma com­pa­nies + more

Last year
Deals
AI

#JPM24 quick hits: A 'great year for M&A'; an op­ti­mistic Sarep­ta; Pfiz­er's CEO + more

Last year
Deals
R&D

Rhythm li­cens­es obe­si­ty drug for $100M; Gala­pa­gos teams up with Brid­Gene; In­sil­i­co’s new deal

Last year
News Briefing

All the new drugs ap­proved in 2023: Alzheimer's and gene ther­a­py cap a five-year high

Last year
FDA+

J&J’s new part­ner­ship with Elek­trofi; Enyo rais­es €39M; Ar­row­head­'s $450M of­fer­ing

Last year
News Briefing

The­seus goes with Tang; Onc­ter­nal tri­al pa­tient dies; Lian­Bio sells drug rights to J&J

Last year
News Briefing

The 2023 win­ners and losers list: Who was up and who was down in bio­phar­ma

Last year
Pharma
First page Previous page 10111213141516 Next page Last page
A service from the Financial Times